Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Next Previous
Trial Profile

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 801 (Primary) ; Docetaxel (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms ARC-27
  • Sponsors Arcus Biosciences

Most Recent Events

  • 25 Feb 2025 According to Arcus Biosciences media release, company anticipates advancing this molecule into expansion cohorts in non-small cell lung cancer (NSCLC) in the second half of 2025.
  • 30 Jan 2025 Treatment part has been amended. ( Zimberelimab has been removed and AB801 has been given in tablet and capsule form).
  • 30 Jan 2025 Planned number of patients changed from 80 to 91.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top